The Philippine Food and Drug Administration (FDA) on Wednesday announced that it had granted emergency use authorization (EUA) to the Covovax Covid-19 vaccine.
In a Laging Handa briefing, FDA chief Eric Domingo said the vaccine, developed by the US-based biotechnology company Novavax, may be administered to individuals aged 18 and above.
Covovax is a two-dose vaccine.
Each dose is administered three to four weeks apart.
“Bagong klase po ng bakuna ito, ito po ay iyong tinatawag na protein-based subunit vaccine na isang party po na pure part of the antigenic na parte po noong virus ang kaniyang niri-replicate pagkatapos ito po ay ini-inject para mag-elicit po ng immune response,” he said.
According to Domingo, Covovax had an 89.7-percent efficacy rate in clinical trials.
“Ito po ay isang possible natin na maaaring magamit na bakuna lalung-lalo na po siguro sa towards the end of the year or sa darating na 2022,” Domingo said. John Ezekiel J. Hirro
